RSV Market Shake Up Starts As Sanofi And AZ’s Beyfortus Wins First Approval
With Blockbuster Sales Potential
The firms’ monoclonal antibody has received the EU green light just months after a positive CHMP opinion with observers projecting billions in peak sales as it becomes the first new RSV prophylactic in decades.
